MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL

Marginal zone lymphoma (MZL) is a common type of indolent lymphoma that originates from the marginal zone of lymphoid follicles. This study aims to evaluate targeted therapy based on the prognostic risk stratification of MZL-IPI in newly diagnosed MZL cases requiring systemic treatment, and provides a basis for precision treatment of MZL.

Trial Details

NCT ID
NCT06793189
Phase
PHASE2
Sponsor
Ruijin Hospital
Status
RECRUITING
Cancer Type
Marginal Zone Lymphoma Lymphoma
Interventions
  • Obinutuzumab and Orelabrutinib
  • Obinutuzumab, Orelabrutinib and Lenalidomide
  • Orelabrutinib
Locations (sample)
  • Shanghai, China, China|31.22222,121.45806
  • Shenyang, Liaoning, China|41.79222,123.43278
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • 1\. Histopathologically confirmed CD20-positive marginal zone lymphoma (according to the 2016 WHO classification).
  • 2\. Age ≥ 18 years old, regardless of gender. 3. MZL patients requiring systemic treatment, including but not limited to:
  • Helicobacter pylori (HP)-positive or HP - negative gastric mucosa extranodal marginal zone lymphoma (MALT) patients with progression/relapse after …
  • Non - gastric MALT patients with Ann Arbor stage I - II who have progression/relapse after local treatment (including surgery, radiotherapy, etc.),…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Marginal Zone Lymphoma Lymphoma Trials on Trialify →